These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 7733640

  • 1. In vitro antitumor activity of a new platinum complex, cis-malonato [(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane] platinum (II) (SKI 2053R), against human lung and stomach cancer cell lines.
    Hong WS, Kim HT, Kim KH, Kim DK.
    Anticancer Res; 1995; 15(1):51-4. PubMed ID: 7733640
    [Abstract] [Full Text] [Related]

  • 2. Antitumor activity of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2- isopropyl-1,3-dioxolane]platinum(II), a new platinum analogue, as an anticancer agent.
    Kim DK, Kim HT, Cho YB, Tai JH, Ahn JS, Kim TS, Kim KH, Hong WS.
    Cancer Chemother Pharmacol; 1995; 35(5):441-5. PubMed ID: 7850928
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics and antitumor activity of a new platinum compound, cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1, 3- dioxolane]platinum(II), as determined by ex vivo pharmacodynamics.
    Kim DK, Kim HT, Tai JH, Cho YB, Kim TS, Kim KH, Park JG, Hong WS.
    Cancer Chemother Pharmacol; 1995; 37(1-2):1-6. PubMed ID: 7497577
    [Abstract] [Full Text] [Related]

  • 4. In vitro cytotoxicity, pharmacokinetics and ex vivo pharmacodynamics of a new platinum compound, cis-malonato [(4R,5R-4,5-bis(aminomethyl)-1,3-dioxolane-2-spiro-1'-cyclopentane] platinum (II).
    Kim DK, Kim HT, Cho YB, Kim TS, Kim KH, Hong WS.
    Anticancer Res; 1996; 16(1):251-6. PubMed ID: 8615617
    [Abstract] [Full Text] [Related]

  • 5. Influence of exposure and infusion times on the cytotoxicity and pharmacokinetics of cis-malonato[(4R, 5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane]platinum(II) .
    Kim HT, Kim DK, Cho YB, Kim TS, Jung I, Kim KH, Heo DS, Bang YJ, Shin SG, Kim NK.
    Cancer Chemother Pharmacol; 1998; 41(2):109-16. PubMed ID: 9443623
    [Abstract] [Full Text] [Related]

  • 6. General pharmacology of cis-malonato[4R,5R)-4,5-bis-(aminomethyl)-2-isopropyl-1,3- dioxolane]platinum(II).
    Kim DK, Ahn JS, Ryu G, Kim KH, Park CW, Kim MS, Chung MH, Shin SG, Suh YH, Kim YS.
    Arzneimittelforschung; 1994 Sep; 44(9):1080-8. PubMed ID: 7986249
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics, tissue distribution, and excretion of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3- dioxolane]platinum(II) in dogs.
    Cho YB, Kim KH, Kim DK.
    Drug Metab Dispos; 1995 Nov; 23(11):1280-5. PubMed ID: 8591731
    [Abstract] [Full Text] [Related]

  • 8. Mammary excretion and placental transfer of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane] platinum(II) in rats.
    Cho YB, Kim KH, Kim DK, Miyamoto G.
    Arzneimittelforschung; 1996 Sep; 46(9):926-30. PubMed ID: 8876944
    [Abstract] [Full Text] [Related]

  • 9. A Phase I study of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-1,3-dioxolane] platinum(II) in patients with advanced malignancies.
    Kim NK, Kim TY, Shin SG, Park YI, Lee JA, Cho YB, Kim KH, Kim DK, Heo DS, Bang YJ.
    Cancer; 2001 Apr 15; 91(8):1549-56. PubMed ID: 11301404
    [Abstract] [Full Text] [Related]

  • 10. In vitro antitumor activity of a new platinum complex, DWA2114R against human tumor cell lines.
    Akamatsu K, Saito H, Tsunenari T, Matsumoto T, Morikawa K, Koizumi M, Mitsui H, Koizumi K.
    Anticancer Res; 1993 Apr 15; 13(6A):2261-5. PubMed ID: 8297143
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1, 3-dioxolane]platinum(II) in rats.
    Cho YB, Kim DK, Kim KH, Miyamoto G.
    Arzneimittelforschung; 1996 Jun 15; 46(6):629-34. PubMed ID: 8767356
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Platinum agents in the treatment of osteosarcoma: efficacy of cisplatin vs. carboplatin in human osteosarcoma cell lines.
    Robson H, Meyer S, Shalet SM, Anderson E, Roberts S, Eden OB.
    Med Pediatr Oncol; 2002 Dec 15; 39(6):573-80. PubMed ID: 12376980
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines.
    Ohe Y, Nakagawa K, Fujiwara Y, Sasaki Y, Minato K, Bungo M, Niimi S, Horichi N, Fukuda M, Saijo N.
    Cancer Res; 1989 Aug 01; 49(15):4098-102. PubMed ID: 2472873
    [Abstract] [Full Text] [Related]

  • 19. In vitro and in vivo antineoplastic activity of a new platinum antineoplastic agent, (R)-(-)-1,1-cyclobutanedicarboxylate (2-aminomethylpyrrolidine)-platinum (II) (DWA2114R) on freshly separated human tumor cells and human tumor xenografts transplanted in nude mice--a comparison with cis-diammine-dichloroplatinum (CDDP).
    Nio Y, Imai S, Shiraishi T, Tsubono M, Morimoto H, Tseng CC, Tobe T.
    Anticancer Res; 1991 Aug 01; 11(2):761-7. PubMed ID: 2064331
    [Abstract] [Full Text] [Related]

  • 20. [Pharmacological approach to the platinum compounds].
    Sasaki Y.
    Gan To Kagaku Ryoho; 1992 Apr 01; 19(4):456-62. PubMed ID: 1313667
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.